HC Wainwright reissued their buy rating on shares of Savara (NASDAQ:SVRA – Free Report) in a report released on Tuesday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.
A number of other equities analysts have also recently commented on SVRA. Guggenheim increased their target price on Savara from $8.00 to $10.00 and gave the company a buy rating in a report on Thursday, June 27th. JMP Securities reaffirmed a market outperform rating and set a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. Finally, Oppenheimer increased their target price on shares of Savara from $11.00 to $15.00 and gave the company an outperform rating in a research report on Wednesday, June 26th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Savara currently has a consensus rating of Buy and an average price target of $11.17.
Check Out Our Latest Report on Savara
Savara Trading Up 4.7 %
Savara (NASDAQ:SVRA – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, equities research analysts forecast that Savara will post -0.44 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Savara
Hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP purchased a new stake in Savara in the fourth quarter valued at $9,683,000. Sivia Capital Partners LLC acquired a new stake in shares of Savara during the 4th quarter worth about $169,000. China Universal Asset Management Co. Ltd. raised its holdings in Savara by 66.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock valued at $130,000 after buying an additional 10,381 shares during the period. BNP Paribas Financial Markets lifted its position in Savara by 92.3% in the first quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock valued at $366,000 after buying an additional 35,269 shares during the last quarter. Finally, Jennison Associates LLC increased its position in shares of Savara by 0.3% during the first quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock valued at $44,033,000 after acquiring an additional 26,613 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.
About Savara
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More
- Five stocks we like better than Savara
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- What Does Downgrade Mean in Investing?
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.